NCT00002352已完成不适用
Pilot Study of the Antiviral Activity of Multiple Doses of Oral Lobucavir in AIDS Patients
Bristol-Myers Squibb6 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 6
研究概览
简要总结
The purpose of this study is to see if lobucavir is a safe and effective treatment for cytomegalovirus in patients with AIDS.
详细描述
Patients receive 1 of 2 doses of lobucavir for 28 days, with 2 weeks of follow-up. Weekly clinic visits are required.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
2 期
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 InfectionHIV/AIDSNCT04560569Frontier Biotechnologies Inc.20
已完成
3 期
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell TransplantationCancerNCT00045292Fred Hutchinson Cancer Center
已完成
2 期
Letermovir Treatment for Refractory or Resistant Cytomegalovirus InfectionCytomegalovirus InfectionsNCT03728426Amy C. Sherman, MD10
进行中（未招募）
2 期
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug ResistanceHIV-1-infectionNCT04150068Gilead Sciences72
已完成
2 期
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabB-Cell Prolymphocytic LeukemiaPeripheral T-Cell LymphomaPrimary Cutaneous T-Cell Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaSezary SyndromeT-Cell Prolymphocytic LeukemiaNCT04312841Ohio State University Comprehensive Cancer Center6